Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


FDA Approves Stemedica Phase II Clinical Trial for Acute Myocardial Infarction with Ischemia Tolerant Mesenchymal Stem Cells 

 

October 2, 2012 - (Stemedica) - "Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) to assess the clinical effects of Stemedyne-MSC (Stemedica’s human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with a myocardial infarct."  Read Full Article

 

Posted on 8-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: